NCT02415621View on ClinicalTrials.gov

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 13, 2015

Primary Completion Date

August 12, 2019

Study Completion Date

July 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone Acetate

1000 mg by mouth (PO) every day (QD)

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER